A century of “intrinsic asthma”

A view on the development of phenotyping in asthma in the last 100 years
review
  • 4 Downloads

Abstract

Background

One hundred years ago Rackemann published the first description of Intrinsic Asthma. This was the beginning of a process of phenotyping the disease.

Materials and methods

The literature regarding asthma phenotypes of the last 100 years has been checked. Lately, there have been many new publications dealing with this specific asthma phenotype.

Conclusion

Today, the term asthma is looked at as an umbrella covering different phenotypes of the disease. According to a recent publication, Intrinsic Asthma is most often cited now as eosinophilic adult-onset asthma. New treatment strategies for this phenotypes have evolved in recent years.

Keywords

Asthma Allergy Intrinsic asthma Eosinophilic asthma Asthma phenotypes 

Notes

Conflict of interest

T. Rothe gave advice and has given lectures for: AstraZeneca, GSK, TEVA, and Novartis Pharma Schweiz.

References

  1. 1.
    Rackemann FM. A clinical study of one hundred and fifty cases of bronchial asthma. Arch Intern Med. 2018;2:517–22.Google Scholar
  2. 2.
    Virchow C. Intrinsic Asthma: Symptome, Gesamt-IgE Spiegel, Pathophysiologie. Prax Pneumol. 1973;10:578–572.Google Scholar
  3. 3.
    Turner-Warwick M. On observing patterns of airway obstruction in chronic asthma. Br J Dis Chest. 1977;71:73–86.CrossRefPubMedGoogle Scholar
  4. 4.
    Haldar P, Pavord ID, Shaw DE, Berry MA, Thomas M, Brightling CE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med. 2008;178:218–24.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Amelink M, de Groot JC, de Nijs SB, Lutter R, Zwinderman AH, Sterk PJ, et al. Severe adult-onset asthma: a distinct phenotype. J Allergy Clin Immunol. 2013;132:336–41.CrossRefPubMedGoogle Scholar
  6. 6.
    Brusselle G, Maes T, Bracke K. Eosinophils in the spotlight: eosinophilic airway inflammation in nonallergic asthma. Nat Med. 2013;19(8):977.  https://doi.org/10.1038/nm.3300. http://www.nature.com/nm/journal/v19/n8/full/nm.3300.html.CrossRefPubMedGoogle Scholar
  7. 7.
    Künzli N, Bridevaux PO, Liu LJ, Garcia-Esteban R, Schindler C, Gerbase MW et al. Traffic-related air pollution correlates with adult-onset asthma among never-smokers. Thorax. 2009;64:664–70.CrossRefPubMedGoogle Scholar
  8. 8.
    Coogan PF, Castro-Webb N, Yu J, O’Connor GT, Palmer JR, Rosenberg L. Active and passive smoking and the incidence of asthma in the black women’s health study. Am J Respir Crit Care Med. 2015;191:168–76.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Westerhof GA, Vollema EM, Weersink EJ, Reinartz SM, de Nijs SB, Bel EH. Predictors for the development of progressive severity in new-onset adult asthma. J Allergy Clin Immunol. 2014;134:1051–6.CrossRefPubMedGoogle Scholar
  10. 10.
    www.ginasthma.org. Accessed January 15. 2018
  11. 11.
    www.goldcopd.org. Accessed January 15. 2018
  12. 12.
    Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M, et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax. 2006;61:671–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sin DD, Miravitlles M, Mannino DM, Soriano JB, Price D, Celli BR, et al. What is asthma—COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48:664–73.CrossRefPubMedGoogle Scholar
  14. 14.
    Bafadhel M, Greening NJ, Harvey-Dunstan TC, Williams JE, Morgan MD, Brightling CE, et al. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest. 2016;150:320–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377:1613–29.CrossRefPubMedGoogle Scholar
  17. 17.
    Wenzel S. Defining of the persistent adult phenotypes. Lancet. 2006;368:804–13.CrossRefPubMedGoogle Scholar
  18. 18.
    Ruffilli A, Bonini S. Susceptibility genes for allergy and asthma. Allergy. 1997;52:256–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Wagener AH, Nijs SB, Lutter R, Sousa AR, Weersink EJ, Bel EH, et al. External validation of blood eosinophils, FeNO and serum periostin as surrogates for sputum eosinophils in asthma. Thorax. 2015;70:115–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Wüthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Int Arch Allergy Immunol. 1995;106:149–56.CrossRefPubMedGoogle Scholar
  21. 21.
    Rothe T. High-altitude sojourn: a treatment option in allergic asthma. Swiss Med Wkly. 2013;143:w13833.PubMedGoogle Scholar
  22. 22.
    Bel EH, Wenzel SE, Thompson PF, et al. Oral glucocorticoid sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371:1189–97.CrossRefPubMedGoogle Scholar
  23. 23.
    Chung KF, Wenzel SE, Brozek L, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–73.CrossRefPubMedGoogle Scholar
  24. 24.
    Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150:789–98.CrossRefPubMedGoogle Scholar
  25. 25.
    Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. N Engl J Med. 2017;376:2448–58.CrossRefPubMedGoogle Scholar
  26. 26.
    Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin Immunol. 2017;140:1024–31.CrossRefPubMedGoogle Scholar
  27. 27.
    Al Samri MR, Benedetti A, Préfontaine D, Olivenstein R, Lemière C, Nair P, et al. Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: a prospective study using multiple samples. J Allergy Clin Immunol. 2010;125:1161–3.CrossRefGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, a part of Springer Nature 2018

Authors and Affiliations

  1. 1.PneumologieKantonsspital GraubündenChurSwitzerland

Personalised recommendations